Efficacious 11β-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model

Journal of Medicinal Chemistry

Volumn 52, Issue 17, 2009, Pages 5449-5461

  Wan, Zhao Kui ^a   Chenail, Eva ^a   Xiang, Jason ^a   Li, Huan Qiu ^a   Ipek, Manus ^a   Bard, Joel ^a   Svenson, Kristine ^a   Mansour, Tarek S ^a   Xu, Xin ^a   Tian, Xianbin ^a   Suri, Vipin ^a   Hahm, Seung ^a   Xing, Yuzhe ^a   Johnson, Christian E ^a   Li, Xiangping ^a   Qadri, Ariful ^a   Panza, Darrell ^a   Perreault, Mylene ^a   Tobin, James F ^a   Saiah, Eddine ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 3 CHLORO 4 [[4 [4 FLUORO 2 (TRIFLUOROMETHYL)PHENYL] 2 METHYLPIPERAZIN 1 YL]SULFONYL]BENZAMIDE; BENZENESULFONAMIDE DERIVATIVE; CORTISONE; GLUCOCORTICOID RECEPTOR; GLUCOSE; HYDROCORTISONE; INSULIN; UNCLASSIFIED DRUG; ENZYME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIABETES MELLITUS; DIET; DRUG EFFICACY; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; MALE; MOUSE; NONHUMAN; OBESITY; STRUCTURE ACTIVITY RELATION; ANIMAL; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL; CONFORMATION; CRICETULUS; DISEASE MODEL; DRUG ANTAGONISM; DRUG DESIGN; ENZYMOLOGY; HAMSTER; IC 50; X RAY CRYSTALLOGRAPHY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; CRYSTALLOGRAPHY, X-RAY; DIET; DISEASE MODELS, ANIMAL; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; OBESITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 69949107020     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900639u     Document Type: Article

References (44)

1. Zimmet, P. Z.; Alberti, K. G.; Shaw, J. Global and societal implications of the diabetes epidemic. Nature 2001, 414, 782-787.
2. Day, C. Metabolic syndrome, or what you will: definitions and epidemiology. Diabetes Vasc. Dis. Res. 2007, 4, 32-38.
3. Mohler, M. L.; He, Y.; Wu, Z.; Hwang, D. J.; Miller, D. D. Recent and emerging anti-diabetes targets. Med. Res. Rev. 2009, 29, 125-195.
4. (a) Tomlinson, J. W.; Walker, E. A.; Bujalska, I. J.; Draper, N.; Lavery, G. G.; Cooper, M. S.; Hewison, M.; Stewart, P. M. 11β-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev. 2004, 25, 831-866.
5. (b) Stulnig, T. M.; Waldhausl, W. 11β-Hydroxysteroid dehydrogenase type 1 in obesity and type 2 diabetes. Diabetologia 2004, 47, 1-11. (Pubitemid 38141933)
6. (a) Masuzaki, H.; Peterson, J.; Shinyama, H.; Morton, N. M.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294, 2166-2170. (Pubitemid 33150673)
7. (b) Masuzaki, H.; Yamamoto, H.; Kenyon, C. J.; Elmquist, J. K.; Morton, N. M.; Paterson, M. M.; Shinyama, H.; Sharp, M. G.; Fleming, S.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 2003, 112, 83-88.
8. Paterson, J. M.; Morton, N. M.; Fievet, C.; Kenyon, C. J.; Holmes, M. C.; Staels, B.; Seckl, J. R.; Mullins, J. J. Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 7088-7093.
9. Morton, N. M.; Paterson, M.; Masuzaki, H.; Holmes, M.; Staels, B.; Fievet, C.; Walker, B.; Flier, J. S.; Mullins, J. J.; Seckl, J. R. Novel adipose tissue- mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type-1 deficient mice. Diabetes 2004, 53, 931-938.
10. For a review, see: (a) Saiah, E. The role of 11beta-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11beta-HSD1 inhibitors. Curr. Med. Chem. 2008, 15, 642-649
11. Recently reported 11β-HSD1 inhibitors: . (b) Sun, D.; Wang, Z.; Di, Y.; Jaen, J. C.; Labelle, M.; Ma, J.; Miao, S.; Sudom, A.; Tang, L.; Tooka, C. S.; Tu, H.; Ursu, S.; Walker, N.; Yan, X.; Ye, Q.; Powers, J. P. Discovery and Initial SAR of Arylsulfonylpiperazine Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1). Bioorg. Med. Chem. Lett. 2008, 18, 3513-3516.
12. Aster, S. D.; Graham, D. W.; Kharbanda, D.; Patel, G.; Ponpipom, M.; Santorelli, G. M.; Szymonifka, M. J.; Mundt, S. S.; Shah, K.; Springer, M. S.; Thieringer, R.; Hermanowski-Vosatka, A.; Wright, S. D.; Xiao, J.; Zokian, H.; Balkovec, J. M. Bisaryl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. Lett. 2008, 18, 2799-2804.
13. St. Jean, D. J.; Yuan, C.; Bercot, E. A.; Cupples, R.; Chen, M.; Fretland, J.; Hale, C.; Hungate, R. W.; Komorowski, R.; Veniant, M.; Wang, M.; Zhang, X.; Fotsch, C. 2-(S)-Phenethylaminothiazolones as potent, orally efficacious inhibitors of 11β-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 2007, 50, 429-432.
14. (e) Rohde, J. J.; Pliushchev, M. A.; Sorensen, B. K.; Wodka, D.; Shuai, Q.; Wang, J.; Fung, S.; Monzon, K. M.; Chiou, W. J.; Pan, L.; Deng, X.; Chovan, L. E.; Ramaiya, A.; Mullally, M.; Henry, R. F.; Stolarik, D. F.; Imade, H. M.; Marsh, K. C.; Beno, D. W. A.; Fey; Thomas, A.; Droz, B. A.; Brune, M. E.; Camp, H. S.; Sham, H. L.; Frevert, E. U.; Jacobson, P. B.; Link, J. T. Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11β-hydroxysteroid dehydrogenase type 1 inhibitors. J. Med. Chem. 2007, 50, 149-164.
15. (f) Xiang, J.; Ipek, M.; Suri, V.; Tam, M.; Xing, Y.; Huang, N.; Zhang, Y.; Tobin, J.; Mansour, T.; McKew, J. β-Keto sulfones as inhibitors of 11β-hydroxysteroid dehydrogenase type 1 and the mechanism of action. Bioorg. Med. Chem. 2007, 15, 4396-4405.
16. (g) Sorensen, B.; Winn, M.; Rohde, J.; Shuai, Q.; Wang, J.; Fung, S.; Monzon, K.; Chiou, W.; Stolarik, D.; Imade, H.; Pan, L.; Deng, X.; Chovan, L.; Longenecker, K.; Judge, R.; Qin, W.; Brune, M.; Camp, H.; Frevert, E. U.; Jackbson, P.; Link, J. T. Adamantane sulfone and sulfonamide 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 527-532
17. (h) Yeh, V.; Kurukulasuriya, R.; Madar, D.; Patel, J.; Fung, S.; Monzon, K.; Chiou, W.; Wang, J.; Jacobson, P.; Sham, H.; Link, J. Synthesis and structural activity relationship of 11β-HSD1 inhibitors with novel adamantane replacements. Bioorg. Med. Chem. Lett. 2006, 16, 5408-5413.
18. (i) Schuster, D.; Maurer, E.; Laggner, C.; Nashev, L.; Wilckens, T.; Langer, T.; Odermatt, A. The discovery of new 11β-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. J. Med. Chem. 2006, 49, 3454-3466.
19. (j) Gu, X.; Dragovic, J.; Koo, G. C.; Koprak, S. L.; LeGrand, C.; Mundt, S. S.; Shah, K.; Springer, M.; Tan, E.; Thieringer, R.; Hermanowski- Vosatka, A.; Zokian, H.; Balkovec, J.; Waddell, S. T. Discovery of 4-heteroarylbicyclo[2. 2.2]octyltriazoles as potent and selective inhibitors of 11β-HSD1: Novel therapeutic agents for the treatment of metabolic syndrome. Bioorg. Med. Chem. Lett. 2005, 15, 5266-5269.
20. (k) Olson, S.; Aster, S.; Brown, K.; Carbin, L.; Graham, D.; Hermanowski, A.; LeGrand, C.; Mundt, S.; Robbins, M.; Schaeffer, J.; Slossberg, L.; Szymonifka, M.; Thieringer, R.; Wright, S.; Balkovec, J. Adamantyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. Lett. 2005, 15, 4359-4362.
21. Xiang, J.; Ipek, M.; Suri, V.; Massefski, W.; Pan, N.; Ge, Y.; Tam, M.; Xing, Y.; Tobin, J.; Xu, X.; Tam, S. Synthesis and biological evaluation of sulfonamidooxazoles and β-keto sulfones: selective inhibitors of 11β-hydroxysteroid dehydrogenase type I. Bioorg. Med. Chem. Lett. 2005, 15, 2865-2869.
22. Coppola, G.; Kukkola, P.; Stanton, J.; Neubert, A.; Marcopulos, N.; Bilci, N.; Wang, H.; Tomaselle, H.; Tan, J.; Aicher, T.; Knorr, D.; Jeng, A.; Dardik, B.; Chatelain, R. Perhydroquinolylbenzamides as novel inhibitors of 11β-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 2005, 48, 6696-6712.
23. (a) Barf, T.; Vallgarda, J.; Emond, R.; Haggstrom, C.; Kurz, G.; Nygren, A.; Larwood, V.; Mosialou, E.; Axelsson, K.; Olsson, R.; Engblom, L.; Edling, N.; Ronquist-Nii, Y.; Ohman, B.; Alberts, P.; Abrahmsen, L. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs: discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 2002, 45, 3813-3815.
24. (b) Alberts, P.; Engblom, L.; Edling, N.; Forsgren, M.; Klingstrom, G.; Larsson, C.; Ronquist-Nii, Y.; Ohman, B.; Abrahmsen, L. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002, 45, 1528-1532. (Pubitemid 35352046)
25. Alberts, P.; Nilsson, C.; Selen, G.; Engblom, L. O.; Edling, N. H.; Norling, S.; Klingstrom, G.; Larsson, C.; Forsgren, M.; Ashkzari, M.; Nilsson, C. E.; Fiedler, M.; Bergqvist, E.; Ohman, B.; Bjorkstrand, E.; Abrahmsen, L. B. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003, 144, 4755-4762.
26. Rueckle, T.; Vitte, P. A.; Gotteland, J. P. WO Patent 2005025558, 2005.
27. Hermanowski-Vosatka, A.; Balkovec, J. M.; Cheng, K.; Chen, H. Y.; Hernandez, G. C.; Koo, G. C.; LeGrand, C. B.; Li, Z.; Metzger, M. M.; Mundt, S. S.; Noonan, H.; Nunes, C. N.; Olson, S. H.; Pikounis, B.; Ren, N.; Robertson, N.; Schaeffer, M. M.; Shah, K.; Springer, M. S.; Strack, A. M.; Strowski, M.; Wu, K.; Wu, T.; Xiao, J.; Zhang, B. B.; Wright, S. D.; Thieringer, R. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. 2005, 202, 517-527.
28. Hoff, E. D.; Link, J. T.; Pliushchev, M. M.; Rohde, J. J.; Winn, M. U.S. Patent 20050245533, 2005.
29. Yeh, V. S. C.; Kurukulasuriya, R.; Fung, S.; Monzon, K.; Chiou, W.; Wan, J.; Stolarik, D.; Imade, H.; Shapiro, R.; Knoure-Segel, V.; Bush, E.; Wilcox, D.; Nguyen, H. T.; Brune, M.; Jacobson, P.; Link, J. T. Discovery of orally active butyrolactam 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 5555-5560.
30. Bhat, B. G.; Hosea, N.; Fanjul, A.; Herrera, J.; Chapman, J.; Thalacker, F.; Stewart, P. M.; Rejto, P. A. Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4′-cyano-biphenyl- 4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11β-hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 2008, 324, 299-305.
31. Xiang, J.; Wan, Z.-K.; Li, H.-Q.; Ipek, M.; Binnun, E.; Nunez, J.; Chen, L.; McKew, J. C.; Mansour, T. S.; Xu, X.; Suri, V.; Tam, M.; Xing, Y.; Li, X.; Hahm, S.; Tobin, J.; Saiah, E. Piperazine sulfonamides as potent, selective, and orally available 11β-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model. J. Med. Chem. 2008, 51, 4068-4071.
32. (a) Wagaw, S.; Buchwald, S. L. The synthesis of aminopyridines: a method employing palladium-catalyzed carbon-nitrogen bond formation. J. Org. Chem. 1996, 61, 7240-7241.
33. (b) Old, D. W.; Wolfe, J. P.; Wagaw, S.; Marcoux, J.-F.; Buchwald, S. L. Rational development of practical catalysts for aromatic carbon-nitrogen bond formation. Acc. Chem. Res. 1998, 31, 805-818.
34. (a) Mune, T.; Rogerson, F. M.; Nikkila, H.; Agarwal, A. K.; White, P. C. Human hypertension caused by mutations in the kidney isoenzyme of 11β-hydroxysteroid dehydrogenase. Nat. Genet. 1995, 10, 394-399.
35. (b) Dave-Sharma, S.; Wilson, R. C.; Harbison, M. D.; Newfield, R.; Azar, M. R.; Krozowski, Z. S.; Funder, J. W.; Shackleton, C. H. L.; Bradlow, H. L.; Wei, J.-Q.; Hertecant, J.; Moran, A.; Neiberger, R. E.; Balfe, J. W.; Fattah, A.; Daneman, D.; Akkurt, H. I.; De Santis, C.; New, M. I. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 1998, 83, 2244-2254.
36. Manuscript is under preparation.
37. Adam, T. C.; Epel, E. S. Stress, eating and the reward system. Physiol. Behav. 2007, 91, 449-458.
38. Lambillotte, C.; Gilon, P.; Henquin, J. C. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J. Clin. Invest. 1997, 99, 414-423.
39. Hosfield, D. J.; Wu, Y.; Skene, R. J.; Hilgers, M.; Jennings, A.; Snell, G. P.; Aertgeerts, K. Conformational flexibility in crystal structures of human 11β-hydroxysteroid dehydrogenase type I provide insights into glucocorticoid interconversion and enzyme regulation. J. Biol. Chem. 2005, 280, 4639-4648.
40. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods Enzymol 1997, 276, 307-326. (Pubitemid 27085611)
41. Adams, P. D.; Grosse-Kunstleve, R. W.; Hung, L.-W.; Ioerger, T. R.; McCoy, A. J.; Moriarty, N. W.; Read, R. J.; Sacchettini, J. C.; Sauter, N. K.; Terwilliger, T. C. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2002, 58, 1948-1954.
42. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132.
43. Lovell, S. C.; Davis, I. W.; Arendall, W. B., III; de Bakker, P. I. W.; Word, J. M.; Prisant, M. G.; Richardson, J. S.; Richardson, D. C. Structure validation by CR geometry: φ, ψ, and Cβ deviation. Proteins: Structure, Function, and Genetics 2003, 50, 437-450.
44. DeLano, W. L. The PyMOL User's Manual; DeLano Scientific: Palo Alto, CA, 2002.